Electronic health records from 77 health care organizations in the US were evaluated for a risk for endocarditis among patients with opioid use disorder or cocaine use disorder on the basis of contracting COVID-19.
A team of investigators conducted a study in an attempt to identify factors that predict the risk of developing opioid use disorder following receipt of a first opioid prescription.
Investigators sourced data for this study from Veteran’s Affairs claims.
Investigators report findings from the AVOID-2 trial that evaluated outcomes following prehospital administration of lidocaine or fentanyl for pain associated with STEMI.
Investigators conducted a cohort study to assess the impact of opioid and stimulant use disorder on risk for overdose among a population of previously incarcerated individuals.
Researchers investigated whether buprenorphine use was associated with a lower risk for adverse neonatal outcomes compared with methadone during pregnancy.
RiVive is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
A team of investigators examined the impact of medical marijuana legalization on opioid use for pain management among patients undergoing treatment for cancer.
Is there an association between drug use and severe influenza-associated outcomes, including ICU admission, mechanical ventilation, and death?
The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021.